• Sequana Medical secures EUR 10 million loan facility with Kreos Capital

    Wednesday July 20th 2022

  • Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study and reports disease-modifying profile for Short Term DSR

    Tuesday July 19th 2022

  • Agomab raises additional $40.5 million through Series B extension bringing total amount to $114 million

    Wednesday July 13th 2022

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    Tuesday July 5th 2022

  • Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody┬« drug discovery and development technology in rare diseases

    Tuesday June 28th 2022

  • MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis

    Tuesday June 28th 2022

  • Voxdale opens Dutch branch at innovation hub Brainport Eindhoven

    Tuesday June 28th 2022

  • ImmuneWatch signs licence agreement with UAntwerp and UZA and officially becomes a university spin-off company

    Friday June 24th 2022

  • Your news here?

  • argenx receives positive CHMP opinion for efgartigimod for the treatment of adult patients with generalized myasthenia gravis in Europe

    Friday June 24th 2022

  • Charles River and Ziphius Vaccines collaborate to manufacture saRNA-based vaccine

    Thursday June 23rd 2022

  • Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry

    Thursday June 23rd 2022


Strategic Partners